Cargando…
Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation
BACKGROUND: Chondrosarcoma is characterized for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and low rates of survival. Research within the field of development and expansion of new treatment options for unresectable or metastatic diseases i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641423/ https://www.ncbi.nlm.nih.gov/pubmed/26555773 http://dx.doi.org/10.1186/s12885-015-1915-4 |
_version_ | 1782400202388275200 |
---|---|
author | Lohberger, Birgit Leithner, Andreas Stuendl, Nicole Kaltenegger, Heike Kullich, Werner Steinecker-Frohnwieser, Bibiane |
author_facet | Lohberger, Birgit Leithner, Andreas Stuendl, Nicole Kaltenegger, Heike Kullich, Werner Steinecker-Frohnwieser, Bibiane |
author_sort | Lohberger, Birgit |
collection | PubMed |
description | BACKGROUND: Chondrosarcoma is characterized for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and low rates of survival. Research within the field of development and expansion of new treatment options for unresectable or metastatic diseases is of particular priority. Diacerein, a symptomatic slow acting drug in osteoarthritis (SYSADOA), implicates a therapeutic benefit for the treatment of chondrosarcoma by an antitumor activity. METHODS: After treatment with diacerein the growth behaviour of the cells was analyzed with the xCELLigence system and MTS assay. Cell cycle was examined using flow cytometric analysis, RT-PCR, and western blot analysis of specific checkpoint regulators. The status for phosophorylation of mitogen-activated protein kinases (MAPKs) was analyzed with a proteome profiler assay. In addition, the possible impact of diacerein on apoptosis was investigated using cleaved caspase 3 and Annexin V/PI flow cytometric analysis. RESULTS: Diacerein decreased the cell viability and the cell proliferation in two different chondrosarcoma cell lines in a dose dependent manner. Flow cytometric analysis showed a classical G2/M arrest. mRNA and protein analysis revealed that diacerein induced a down-regulation of the cyclin B1-CDK1 complex and a reduction in CDK2 expression. Furthermore, diacerein treatment increased the phosphorylation of p38α and p38β MAPKs, and Akt1, Akt2, and Akt 3 in SW-1353, whereas in Cal-78 the opposite effect has been demonstrated. These observations accordingly to our cell cycle flow cytometric analysis and protein expression data may explain the G2/M phase arrest. In addition, no apoptotic induction after diacerein treatment, neither in the Cal-78 nor in the SW-1353 cell line was observed. CONCLUSIONS: Our results demonstrate for the first time that the SYSADOA diacerein decreased the viability of human chondrosarcoma cells and induces G2/M cell cycle arrest by CDK1/cyclin B1 down-regulation. |
format | Online Article Text |
id | pubmed-4641423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46414232015-11-12 Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation Lohberger, Birgit Leithner, Andreas Stuendl, Nicole Kaltenegger, Heike Kullich, Werner Steinecker-Frohnwieser, Bibiane BMC Cancer Research Article BACKGROUND: Chondrosarcoma is characterized for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and low rates of survival. Research within the field of development and expansion of new treatment options for unresectable or metastatic diseases is of particular priority. Diacerein, a symptomatic slow acting drug in osteoarthritis (SYSADOA), implicates a therapeutic benefit for the treatment of chondrosarcoma by an antitumor activity. METHODS: After treatment with diacerein the growth behaviour of the cells was analyzed with the xCELLigence system and MTS assay. Cell cycle was examined using flow cytometric analysis, RT-PCR, and western blot analysis of specific checkpoint regulators. The status for phosophorylation of mitogen-activated protein kinases (MAPKs) was analyzed with a proteome profiler assay. In addition, the possible impact of diacerein on apoptosis was investigated using cleaved caspase 3 and Annexin V/PI flow cytometric analysis. RESULTS: Diacerein decreased the cell viability and the cell proliferation in two different chondrosarcoma cell lines in a dose dependent manner. Flow cytometric analysis showed a classical G2/M arrest. mRNA and protein analysis revealed that diacerein induced a down-regulation of the cyclin B1-CDK1 complex and a reduction in CDK2 expression. Furthermore, diacerein treatment increased the phosphorylation of p38α and p38β MAPKs, and Akt1, Akt2, and Akt 3 in SW-1353, whereas in Cal-78 the opposite effect has been demonstrated. These observations accordingly to our cell cycle flow cytometric analysis and protein expression data may explain the G2/M phase arrest. In addition, no apoptotic induction after diacerein treatment, neither in the Cal-78 nor in the SW-1353 cell line was observed. CONCLUSIONS: Our results demonstrate for the first time that the SYSADOA diacerein decreased the viability of human chondrosarcoma cells and induces G2/M cell cycle arrest by CDK1/cyclin B1 down-regulation. BioMed Central 2015-11-10 /pmc/articles/PMC4641423/ /pubmed/26555773 http://dx.doi.org/10.1186/s12885-015-1915-4 Text en © Lohberger et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lohberger, Birgit Leithner, Andreas Stuendl, Nicole Kaltenegger, Heike Kullich, Werner Steinecker-Frohnwieser, Bibiane Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title | Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title_full | Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title_fullStr | Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title_full_unstemmed | Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title_short | Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation |
title_sort | diacerein retards cell growth of chondrosarcoma cells at the g2/m cell cycle checkpoint via cyclin b1/cdk1 and cdk2 downregulation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641423/ https://www.ncbi.nlm.nih.gov/pubmed/26555773 http://dx.doi.org/10.1186/s12885-015-1915-4 |
work_keys_str_mv | AT lohbergerbirgit diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation AT leithnerandreas diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation AT stuendlnicole diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation AT kalteneggerheike diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation AT kullichwerner diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation AT steineckerfrohnwieserbibiane diacereinretardscellgrowthofchondrosarcomacellsattheg2mcellcyclecheckpointviacyclinb1cdk1andcdk2downregulation |